⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Nevakar, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Nevakar, Inc.
↗Bridgewater, New Jersey, USA
Nevakar, Inc. is a specialty pharmaceutical company focused on developing innovative injectable and ophthalmic products. The company utilizes the 505(b)(2) regulatory pathway to reposition existing molecules by developing novel formulations, designing functional packaging, and improving therapeutic indications.
Headquartered in Bridgewater, New Jersey, Nevakar operates through specialized subsidiaries, including Vyluma (ophthalmology) and Nevakar Injectables. The company focuses on addressing unmet medical needs in hospital and ambulatory care settings, with a portfolio spanning critical care, acute pain management, and refractive errors.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2015
Ownership:private
Status:operating
FUNDING
Stage:Private Equity Backed
Investors:H.I.G. Capital, NovaQuest Capital Management
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3 (NVK-002)
Modalities:Small molecule, Injectables, Ophthalmic solutions
Trial Phases:Phase 3: 1
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Vyluma Inc., Nevakar Injectables Inc.
Key Partnerships:Zhaoke Ophthalmology (Greater China/SE Asia licensing for NVK-002), Théa (European licensing for NVK-002), Endo Pharmaceuticals (US/Canada licensing for critical care injectables)
COMPETITION
Position:Niche Player
Competitors:Ensysce Biosciences, Sustained Therapeutics, Concentric Analgesics, G2GBIO
LEADERSHIP
Key Executives:
Navneet Puri - Founder, Chairman and CEO
Scientific Founders:Navneet Puri
Board Members:George S. Zorich (Chairman)
LINKS
Website:nevakar.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Nevakar, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.